Device 300419 Strip
Geistlich Pharma AG · Decision date Jun 2, 2026
What did the FDA decide?
FDA records K260364 as a 510(k) premarket notification, with a decision dated Jun 2, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Jun 2, 2026
Regulatory record facts
- Identifier
- K260364
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Geistlich Pharma AG
- Product code
- MQV
- Decision code
- SESE
- Decision date
- Jun 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Filler, Bone Void, Calcium Compound.
- Applicant
- Geistlich Pharma AG
- Product code
- MQV
- FDA device class
- 2
FDA decision timeline
K260364 received
Application receipt date recorded by FDA.
K260364 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code MQV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PearlBone Putty 1600K260496 | Marine Biomedical | 510(k) clearance | Nov 2, 2026 | FDA |
Mg OSTEOREVIVE;Mg OSTEOCRETEK262230 | Bone Solutions, Inc. | 510(k) clearance | Sep 11, 2026 | FDA |
| Sdip Innovations Pty, Ltd. | 510(k) clearance | May 26, 2026 | FDA | |
| Stryker Spine | 510(k) clearance | Apr 24, 2026 | FDA | |
AdaptosFuse Bone GraftK253524 | Biomendex OY | 510(k) clearance | Feb 17, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Geistlich Pharma AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Wolhusen
Sources and methodology
- Original FDA record: K260364
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



